You are here

Dova Pharmaceuticals to Present at Cowen 38th Annual Health Care Conference

DURHAM, N.C., March 08, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Cowen 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:40 a.m. ET in Boston, Massachusetts.

A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.

About Dova Pharmaceuticals, Inc.

Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.

Contacts

Mark W. Hahn
(919) 338-7936
mhahn@dova.com

Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com

Thursday, March 8, 2018 - 08:00

More Headlines

Conversely, Kids Who Need Drugs Go Untreated
May Reduce the Need for Open-Heart Surgery
NDEA, a Known Carcinogen, Discovered During FDA Testing
Cleared for Adults with Relapsed or Refractory Disease
Approved as Maintenance Treatment for Opioid Dependence
Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic
Study Uses Experimental Software to Decode Variations in Mood
Mixup with Losartan Discovered in Bottles